Consequently, the value of plasma p217+tau appears to lie in the detection of A+ individuals and to reduce the required number of tau PET for trial recruitment by defining a combined Intermediate/Advanced AD stage cohort where tau PET can then be used to separate Advanced from Intermediate stage. The gene discussed is MAPT; the disease is Alzheimer disease.